Bibliografía
(1) Global Health Sector Strategy on Viral Hepatitis 2016-2021. Towards ending viral hepatitis Geneva: World Health Organization; 2016.
(2) Papatheodoridis, G. V., Hatzakis, A., Cholongitas, E, et al. Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe. Journal of Viral Hepatitis, 25(December 2017), 6–17.
(3) Lucidarme D, Decoster A, Fremaux D, et al. Routine practice HCV infection screening with saliva samples: multicentric study in an intravenous drug user population. Gastroenterol Clin Biol 2007; 31:480–484. 17
(4) Schreuder I, van der Sande MA, de Wit M, et al. Seroprevalence of HIV, hepatitis B, and hepatitis C among opioid drug users on methadone treatment in the Netherlands. Harm Reduct J 2010; 7:25.
(5) Yaphe S, Bozinoff N, Kyle R, et al. Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review. Sex Transm Infect 2012; 88:558–564
(6) Zuure FR, Urbanus AT, Langendam MW, Helsper CW, van den Berg CH, Davidovich U, Prins M. Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review. BMC Public Health 2014; 14:66
(7) Heil, J., Soufidi, K., Stals, F., et al. (2019) Retrieval and re-evaluation of previously diagnosed chronic hepatitis C infections lost to medical follow-up in the Netherlands. European Journal of Gastroenterology & Hepatology, 1.
(8) Secretaria General de Sanidad y Consumo. (2018). Plan Estratégico para el Abordaje de la Hepatitis C en el Sistema Nacional de Salud. Ministerio de Sanidad Servicios Sociales E Igualdad, 1–102
(9) European Association for Study of L.iver. EASL Policy Statement on Hepatitis C Elimination. June 2019
(10) Crespo, J., Albillos, A., Buti, M., et al. (2019) Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). Revista Española de Enfermedades Digestivas : Órgano Oficial de La Sociedad Española de Patología Digestiva, 111(11), 862–873.
(11) Ley Orgánica 3/2018, de 5 de diciembre, de Protección de Datos Personales y Garantía de los Derechos Digitales. BOE núm. 294, de 6 de diciembre de 2018, páginas 119788 a 119857
(12) World Medical Association: WMA. Código Internacional de Ética Médica. Adoptado por la 3ª Asamblea General de la AMM Londres, Inglaterra, Octubre 1949 y enmendado por la 22ª Asamblea Médica Mundial Sydney, Australia, Agosto 1968, la 35ª Asamblea Médica Mundial Venecia, Italia, Octubre 1983 y la 57 Asamblea General de la AMM, Pilanesberg, Sudáfrica, Octubre 2006.
(13) Reglamento (UE) 2016/679 del Parlamento Europeo y del Consejo de 27 de abril de 2016, relativo a la protección de las personas físicas en lo que respecta al tratamiento de datos personales y a la libre circulación de estos datos y por el que se deroga la Directiva 95/46/CE (Reglamento general de protección de datos). DOUE núm. 119, de 4 de mayo de 2016, páginas 1 a 88
(14) Collins, FS. BRCA1 — Lots of mutations, lots of dilemmas. The New England Journal of Medicine Jan. 18, 1996
(15) Estadística del Padrón Continuo. Datos provisionales a 1 de enero de 2020. Instituto Nacional de Estadística
(16) Stoové, M., Wallace, J., Higgs, P., et al (2020). Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure. International Journal of Drug Policy, 75, 2019–2020.
(17) Moore, M., Ip, M., Johnson, N., & Laraque, F. (2016). Proactive text messaging as outreach to newly reported individuals with hepatitis C in New York city. Proceedings of the 2016 council of state and territorial epidemiologists conference.
(18) Rogal SS, McCarthy R, Reid A, et al. Primary Care and Hepatology provider-perceived barriers to and facilitators of Hepatitis C treatment candidacy and adherence. Dig Dis Sci 2017;62:1933-1943.
(19) Zhang G, Patel K, Moghe A, et al. Provider perceptions of Hepatitis C treatment adherence and initiation. Dig Dis Sci 2020;65:1324-1333.
(20) Ampuero J, Jimeno C, Quiles R, et al. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. J Hepatol 2018;68:940-948.
(21) Nouch, S., Gallagher, L., Erickson, M., et al. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada. International Journal of Drug Policy, 59 (April 2018), 76–84.
(22) Darvishian, M., Wong, S., Binka, M., et al. Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies. J Viral Hepat 2020;27(3):243-260.
(23) Beekmans, N., & Klemt-Kropp, M. (2018). Re-evaluation of chronic hepatitis B and hepatitis C patients lost to follow-up: results of the Northern Holland hepatitis retrieval project. Hepatology, Medicine and Policy, 3(1), 1–6.
(24) Simpson, H., Manley, P., Lawler, J., et al. (2019). Distance to treatment as a factor for loss to follow up of hepatitis C patients in North East England. Journal of Public Health (United Kingdom), 41(4), 700–706.
(25) Balkhy, H. H., El-Saed, A., Sanai, F. M., et al. Magnitude and causes of loss to follow-up among patients with viral hepatitis at a tertiary care hospital in Saudi Arabia. Journal of Infection and Public Health, 10(4), 379–387
(26) Kracht, P. A. M., Arends, J. E., van Erpecum, K. J., et al. (2019). REtrieval And cure of Chronic Hepatitis C (REACH): Results of micro-elimination in the Utrecht province. Liver International, 39(3), 455–462.